SCHEMBL20554244

SCHEMBL20554244

C#Cc1ccc(COc2ccc(NC(=O)C=C)c3cccnc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.41
PTPN11 Q06124 1/20 0.41
EGFR P00533 5/20 0.41
FGFR4 P22455 4/20 0.41
KDR P35968 2/20 0.40
SLC40A1 Q9NP59 1/20 0.39
MAPT P10636 3/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ERBB2 P04626 1/20 0.38
BTK Q06187 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PDE4D Q08499 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
GRIN2B Q13224 1/20 0.36
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20554145 0.87 SLC40A1 (0.51) PTPN1PTPN11EGFRFGFR4KDR
SCHEMBL29259247 0.85 MAPT (0.47) PTPN1PTPN11EGFRFGFR4KDR
SCHEMBL20554543 0.74 PTPN1 (0.51) PTPN1PTPN11EGFRFGFR4KDM4E
SCHEMBL20554606 0.74 PTPN1 (0.48) PTPN1PTPN11FGFR4KDRKDM4E
SCHEMBL20554396 0.73 PDE4D (0.47) PTPN1PTPN11EGFRKDRPDE4D
SCHEMBL20554427 0.72 PDE4D (0.46) PTPN1PTPN11EGFRKDRPDE4D
SCHEMBL20554080 0.72 BRD4 (0.46) PTPN1PTPN11EGFRFGFR4KDR
SCHEMBL20554377 0.71 PDE4D (0.53) PTPN1PTPN11EGFRFGFR4KDR
SCHEMBL20554317 0.71 PDE4D (0.47) PTPN1PTPN11EGFRKDRBTK
SCHEMBL18347692 0.70 SLC40A1 (0.51) SLC40A1HDAC6SMN1; SMN2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
US-11332455-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-05-17 US disclosed
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-12-09 US disclosed
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-05-27 US disclosed
US-10787428-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2020-09-29 US disclosed
EP-3712129-A1 ALPHA, BETA-UNSATURATED AMIDE COMPOUND Kyowa Kirin Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN disclosed
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-01-10 US disclosed
EP-3401309-A1 a, ß UNSATURATED AMIDE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, RXRA PTPN1 2422/4885PTPN11 2773/4885EGFR 613/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB PTPN1 2080/4885PTPN11 2511/4885EGFR 492/4885
US-10787428-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 PTPN1 2061/4885PTPN11 2609/4885EGFR 457/4885
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 PTPN1 2461/4885PTPN11 2952/4885EGFR 605/4885
US-11332455-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 PTPN1 2061/4885PTPN11 2609/4885EGFR 457/4885
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 PTPN1 2461/4885PTPN11 2952/4885EGFR 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.